Gilead Sciences (GILD) Construction in Progress (2010 - 2025)
Gilead Sciences (GILD) posted Construction in Progress of $745.0 million for Q4 2025, up 48.7% quarter-over-quarter from $501.0 million in Q4 2024, and up 48.7% year-on-year from $501.0 million in Q4 2024.
Gilead Sciences (GILD) Construction in Progress (2010 - 2025) Analysis & Trends
Gilead Sciences (GILD) has reported Construction in Progress for 16 consecutive years, with $745.0 million the latest figure, recorded in Q4 2025.
- Construction in Progress for Q4 2025 came in at $745.0 million, up 48.7% year-over-year; the trailing twelve-month figure through Dec 2025 was $745.0 million (up 48.7% YoY), and the FY2025 annual result was $745.0 million, up 48.7% from the prior year.
- Construction in Progress was $745.0 million for Q4 2025 at Gilead Sciences, up from $501.0 million in the prior quarter.
- Over five years, Construction in Progress peaked at $1.1 billion in Q4 2021 and troughed at $501.0 million in Q4 2024.
- Average Construction in Progress over 5 years is $736.6 million, with a median of $719.0 million recorded in 2022.
- Year-over-year, Construction in Progress sank 31.98% in 2022 and soared 48.7% in 2025.
- Over 5 years, Construction in Progress stood at $1.1 billion in 2021, then tumbled by 31.98% to $719.0 million in 2022, then dropped by 8.07% to $661.0 million in 2023, then dropped by 24.21% to $501.0 million in 2024, then jumped by 48.7% to $745.0 million in 2025.
- Per Business Quant data, the three most recent Construction in Progress figures were $745.0 million in Q4 2025, $501.0 million in Q4 2024, and $661.0 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 745.00 Mn |
| Dec 31, 2024 | 501.00 Mn |
| Dec 31, 2023 | 661.00 Mn |
| Dec 31, 2022 | 719.00 Mn |
| Dec 31, 2021 | 1.06 Bn |
| Dec 31, 2020 | 856.00 Mn |
| Dec 31, 2019 | 723.00 Mn |
| Dec 31, 2018 | 1.19 Bn |
| Dec 31, 2017 | 690.00 Mn |
| Dec 31, 2016 | 641.00 Mn |
| Dec 31, 2015 | 554.00 Mn |
| Dec 31, 2014 | 411.00 Mn |
| Dec 31, 2013 | 129.00 Mn |
| Dec 31, 2012 | 216.43 Mn |
| Dec 31, 2011 | 60.75 Mn |
| Dec 31, 2010 | 82.33 Mn |